Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / Fund iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker DRDR(GBX) LSE
ETF Ticker 2B78(EUR) F
ETF Ticker 2B78.DE(EUR) CXE
ETF Ticker DRDR.LS(GBX) CXE
ETF Ticker HEAL.AS(EUR) CXE
ETF Ticker HEAL.LS(USD) CXE
ETF Ticker HEALz(USD) CXE
ETF Ticker HEAL(EUR) ETF Plus
ETF Ticker DRDR.L(GBP) LSE

Holdings detail for MYGN

Stock Name	Myriad Genetics Inc
Ticker	MYGN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US62855J1043
LEI	52990044IHUOUMETT163

Show aggregate MYGN holdings

News associated with MYGN

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $14.38 Consensus PT from Analysts: Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have been assigned a consensus rating of “Hold” from the sixteen brokerages that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the […] - 2025-08-07 03:12:46
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 86,973 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 43.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 285,229 shares of the company’s stock after purchasing an additional 86,973 shares […] - 2025-06-05 06:14:55
Squarepoint Ops LLC Acquires 29,524 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Squarepoint Ops LLC boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 27.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 138,869 shares of the company’s stock after acquiring an additional 29,524 shares during the period. Squarepoint […] - 2025-05-30 05:34:51
ProShare Advisors LLC Has $370,000 Stake in Myriad Genetics, Inc. (NASDAQ:MYGN): ProShare Advisors LLC grew its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 12.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,982 shares of the company’s stock after purchasing an additional 2,933 shares during the period. ProShare Advisors LLC’s holdings […] - 2025-05-29 05:04:50
BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): BNP Paribas Financial Markets boosted its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 51.1% in the fourth quarter, HoldingsChannel reports. The firm owned 69,183 shares of the company’s stock after buying an additional 23,408 shares during the quarter. BNP Paribas Financial Markets’ holdings in Myriad Genetics were worth $948,000 as of its […] - 2025-05-22 04:28:50
Myriad Genetics, Inc. (NASDAQ:MYGN) Stake Raised by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 4.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 197,001 shares of the company’s stock after purchasing an additional 8,073 […] - 2025-05-21 05:40:50
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Comerica Bank: Comerica Bank trimmed its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 7.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,747 shares of the company’s stock after selling 2,525 shares during the period. Comerica Bank’s holdings in Myriad […] - 2025-05-16 05:20:57
Tudor Investment Corp ET AL Boosts Stake in Myriad Genetics, Inc. (NASDAQ:MYGN): Tudor Investment Corp ET AL boosted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 212.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,935 shares of the company’s stock after acquiring an additional 33,937 shares […] - 2025-05-08 06:12:54
Hsbc Holdings PLC Buys 9,997 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Hsbc Holdings PLC grew its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 49.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,214 shares of the company’s stock after purchasing an additional 9,997 shares during the quarter. Hsbc Holdings […] - 2025-05-08 05:22:47
First Trust Advisors LP Sells 46,831 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): First Trust Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 25.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 139,545 shares of the company’s stock after selling 46,831 shares during the quarter. First Trust Advisors LP […] - 2025-05-06 05:41:06
Dimensional Fund Advisors LP Has $31.15 Million Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN): Dimensional Fund Advisors LP decreased its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 6.2% in the fourth quarter, HoldingsChannel reports. The firm owned 2,272,355 shares of the company’s stock after selling 151,122 shares during the period. Dimensional Fund Advisors LP’s holdings in Myriad Genetics were worth $31,154,000 at the end of the […] - 2025-05-06 04:42:53
How The Pieces Add Up: IJR Headed For $129: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-05 08:51:52
Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target at $20.61: Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned an average recommendation of “Hold” from the sixteen analysts that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. […] - 2025-04-29 02:50:53
Legal & General Group Plc Has $3.38 Million Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN): Legal & General Group Plc decreased its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 246,146 shares of the company’s stock after selling 5,363 shares during […] - 2025-04-23 05:58:48
Arrowstreet Capital Limited Partnership Sells 24,519 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Arrowstreet Capital Limited Partnership cut its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 13.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,062 shares of the company’s stock after selling 24,519 shares during the period. Arrowstreet […] - 2025-04-11 06:07:13
KLP Kapitalforvaltning AS Purchases New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN): KLP Kapitalforvaltning AS acquired a new position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,000 shares of the company’s stock, valued at approximately $247,000. Several other institutional investors and hedge funds have also recently added […] - 2025-04-08 04:32:51
Corebridge Financial Inc. Sells 3,716 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Corebridge Financial Inc. decreased its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 7.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 47,667 shares of the company’s stock after selling 3,716 shares during the quarter. Corebridge Financial Inc.’s holdings in Myriad Genetics were worth $654,000 at the end of the most recent […] - 2025-04-07 04:32:49
Prudential Financial Inc. Sells 126,550 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Prudential Financial Inc. lessened its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 37.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 209,131 shares of the company’s stock after selling 126,550 shares during the period. Prudential […] - 2025-04-03 05:18:51
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $20.00 by Analysts at Scotiabank: Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price lowered by Scotiabank from $24.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “sector outperform” rating on the stock. Scotiabank’s price objective indicates a potential upside of 127.27% from the company’s current price. Several other research […] - 2025-04-03 04:24:52
Myriad Genetics (NASDAQ:MYGN) Stock Rating Upgraded by StockNews.com: StockNews.com upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. Several other research analysts have also commented on MYGN. Stephens reissued an “equal weight” rating and issued a $20.00 price objective on shares of Myriad Genetics in a research report […] - 2025-03-26 04:38:45
Natixis Advisors LLC Sells 110,685 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Natixis Advisors LLC reduced its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 34.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,328 shares of the company’s stock after selling 110,685 shares during the quarter. Natixis Advisors LLC […] - 2025-03-24 05:54:59
Victory Capital Management Inc. Has $841,000 Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN): Victory Capital Management Inc. lifted its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 6.4% during the 4th quarter, HoldingsChannel reports. The fund owned 61,341 shares of the company’s stock after buying an additional 3,711 shares during the period. Victory Capital Management Inc.’s holdings in Myriad Genetics were worth $841,000 as of its […] - 2025-03-21 07:10:48
AlphaQuest LLC Sells 5,360 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): AlphaQuest LLC lowered its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 67.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 2,641 shares of the company’s stock after selling 5,360 shares during the quarter. AlphaQuest LLC’s holdings in Myriad Genetics were worth $36,000 at the end of the most […] - 2025-03-21 06:08:54
Myriad Genetics (NASDAQ:MYGN) Downgraded by StockNews.com to “Hold”: StockNews.com cut shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research note released on Thursday. A number of other equities research analysts also recently issued reports on the company. Morgan Stanley lowered their price objective on Myriad Genetics from $32.00 to $21.00 and set an […] - 2025-03-14 06:04:51
Nasdaq Climbs as Retaliatory Tariffs Spark Mixed Session on Wall Street: The S&P 500 Index ($SPX ) (SPY ) today is up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.43%. March E-mini S&P futures (ESH25 ) are up +0.79%, and March E-mini Nasdaq futures... - 2025-03-12 18:27:33
Myriad Genetics (NASDAQ:MYGN) Given New $11.50 Price Target at Piper Sandler: Myriad Genetics (NASDAQ:MYGN – Free Report) had its price objective cut by Piper Sandler from $14.00 to $11.50 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock. Several other equities research analysts have also commented on MYGN. Leerink Partners lowered Myriad Genetics from an […] - 2025-03-05 06:45:04
Handelsbanken Fonder AB Acquires 3,500 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN): Handelsbanken Fonder AB boosted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 12.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,788 shares of the company’s stock after acquiring an additional 3,500 shares during the quarter. Handelsbanken Fonder AB’s holdings […] - 2025-03-03 06:59:05
Raymond James Reiterates Outperform Rating for Myriad Genetics (NASDAQ:MYGN): Raymond James reaffirmed their outperform rating on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a research report report published on Tuesday,Benzinga reports. They currently have a $19.00 price objective on the stock, down from their previous price objective of $27.00. Other research analysts have also recently issued reports about the company. Bank of […] - 2025-02-26 06:56:56
Myriad Genetics (NASDAQ:MYGN) Hits New 1-Year Low Following Weak Earnings: Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) hit a new 52-week low during trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $9.76 and last traded at $11.63, with a volume of 405660 shares changing hands. The stock had previously closed at $13.78. The company reported ($0.09) EPS for […] - 2025-02-26 04:20:57
New York State Teachers Retirement System Reduces Stake in Myriad Genetics, Inc. (NASDAQ:MYGN): New York State Teachers Retirement System trimmed its stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,598 shares of the company’s stock after selling 3,302 shares during the […] - 2025-02-24 06:26:57

iShares Healthcare Innovation UCITS ETF USD (Acc) MYGN holdings

Date	Number of MYGN Shares Held	Base Market Value of MYGN Shares	Local Market Value of MYGN Shares	Change in MYGN Base Value	Current Price per MYGN Share Held	Previous Price per MYGN Share Held
2025-11-11 (Tuesday)	111,803	USD 746,844	USD 746,844	USD 22,361	USD 6.68	USD 6.48
2025-11-10 (Monday)	111,803	USD 724,483	USD 724,483	USD 20,124	USD 6.48	USD 6.3
2025-11-07 (Friday)	111,803	USD 704,359	USD 704,359	USD -3,354	USD 6.3	USD 6.33
2025-11-06 (Thursday)	111,803	USD 707,713	USD 707,713	USD -27,951	USD 6.33	USD 6.58
2025-11-05 (Wednesday)	111,803	USD 735,664	USD 735,664	USD 13,417	USD 6.58	USD 6.46
2025-11-04 (Tuesday)	111,803	USD 722,247	USD 722,247	USD -192,302	USD 6.46	USD 8.18
2025-11-03 (Monday)	111,803	USD 914,549	USD 914,549	USD 15,653	USD 8.18	USD 8.04
2025-10-31 (Friday)	111,803	USD 898,896	USD 898,896	USD 10,062	USD 8.04	USD 7.95
2025-10-30 (Thursday)	111,803	USD 888,834	USD 888,834	USD 4,472	USD 7.95	USD 7.91
2025-10-29 (Wednesday)	111,803	USD 884,362	USD 884,362	USD -24,596	USD 7.91	USD 8.13
2025-10-28 (Tuesday)	111,803	USD 908,958	USD 908,958	USD 3,354	USD 8.13	USD 8.1
2025-10-27 (Monday)	111,803	USD 905,604	USD 905,604	USD -5,590	USD 8.1	USD 8.15

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MYGN by Blackrock for IE00BYZK4776

Show aggregate share trades of MYGN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-10-24 SELL -958 8.150 8.160 8.159 USD -7,816 9.81 Profit of 1,583 on sale
2025-09-11 BUY 484 7.680 7.710 7.707 USD 3,730 10.07
2025-07-08 SELL -480 5.550 5.560 5.559 USD -2,668 10.50 Profit of 2,370 on sale
2025-06-24 SELL -494 5.050 5.100 5.095 USD -2,517 10.83 Profit of 2,833 on sale
2025-06-23 SELL -494 4.860 4.950 4.941 USD -2,441 10.87 Profit of 2,931 on sale
2025-06-11 SELL -487 5.180 5.340 5.324 USD -2,593 11.23 Profit of 2,877 on sale
2025-05-30 SELL -490 4.190 4.240 4.235 USD -2,075 11.65 Profit of 3,632 on sale
2025-05-21 BUY 489 4.070 4.360 4.331 USD 2,118 12.11
2025-05-14 SELL -2,922 3.840 4.220 4.182 USD -12,220 12.39 Profit of 23,994 on sale
2025-04-30 SELL -480 7.410 7.550 7.536 USD -3,617 13.05 Profit of 2,647 on sale
2025-04-28 SELL -481 7.500 7.710 7.689 USD -3,698 13.17 Profit of 2,634 on sale
2025-04-25 SELL -480 7.420 7.430 7.429 USD -3,566 13.22 Profit of 2,782 on sale
2025-04-11 SELL -2,928 8.000 8.050 8.045 USD -23,556 13.72 Profit of 16,612 on sale
2025-04-08 SELL -1,452 7.730 8.490 8.414 USD -12,217 13.91 Profit of 7,986 on sale
2025-04-07 BUY 8,009 8.070 8.630 8.574 USD 68,669 13.98
2025-03-31 SELL -898 8.870 9.020 9.005 USD -8,086 14.24 Profit of 4,703 on sale
2025-03-21 SELL -892 10.010 10.300 10.271 USD -9,162 14.62 Profit of 3,875 on sale
2025-03-12 SELL -454 10.410 11.440 11.337 USD -5,147 15.08 Profit of 1,701 on sale
2025-02-28 SELL -452 10.730 11.220 11.171 USD -5,049 15.71 Profit of 2,052 on sale
2025-02-25 BUY 450 11.740 12.280 12.226 USD 5,502 15.93
2025-02-20 SELL -450 14.980 15.190 15.169 USD -6,826 16.02 Profit of 382 on sale
2025-02-19 BUY 900 14.900 15.470 15.413 USD 13,872 16.04
2025-02-18 BUY 450 14.570 14.900 14.867 USD 6,690 16.07
2024-12-30 SELL -866 13.630 13.830 13.810 USD -11,959 17.88 Profit of 3,527 on sale
2024-12-06 SELL -441 15.130 16.630 16.480 USD -7,268 18.16 Profit of 741 on sale
2024-12-04 SELL -441 16.600 16.830 16.807 USD -7,412 18.28 Profit of 649 on sale
2024-12-03 SELL -884 16.230 16.710 16.662 USD -14,729 18.36 Profit of 1,497 on sale
2024-11-21 SELL -448 15.120 15.610 15.561 USD -6,971 19.35 Profit of 1,696 on sale
2024-11-20 SELL -459 15.300 15.330 15.327 USD -7,035 19.57 Profit of 1,948 on sale
2024-11-19 SELL -459 15.000 15.680 15.612 USD -7,166 19.84 Profit of 1,941 on sale
2024-11-18 SELL -1,776 15.220 15.510 15.481 USD -27,494 20.13 Profit of 8,254 on sale
2024-11-12 SELL -444 16.170 17.450 17.322 USD -7,691 20.39 Profit of 1,363 on sale
2024-11-07 SELL -443 17.670 18.420 18.345 USD -8,127 20.83 Profit of 1,102 on sale
2024-11-05 SELL -886 17.610 17.960 17.925 USD -15,882 21.42 Profit of 3,097 on sale
2024-10-28 SELL -443 21.960 22.120 22.104 USD -9,792 22.17 Profit of 29 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-24	SELL	-958	8.150	8.160	8.159	USD -7,816	9.81 Profit of 1,583 on sale
2025-09-11	BUY	484	7.680	7.710	7.707	USD 3,730	10.07
2025-07-08	SELL	-480	5.550	5.560	5.559	USD -2,668	10.50 Profit of 2,370 on sale
2025-06-24	SELL	-494	5.050	5.100	5.095	USD -2,517	10.83 Profit of 2,833 on sale
2025-06-23	SELL	-494	4.860	4.950	4.941	USD -2,441	10.87 Profit of 2,931 on sale
2025-06-11	SELL	-487	5.180	5.340	5.324	USD -2,593	11.23 Profit of 2,877 on sale
2025-05-30	SELL	-490	4.190	4.240	4.235	USD -2,075	11.65 Profit of 3,632 on sale
2025-05-21	BUY	489	4.070	4.360	4.331	USD 2,118	12.11
2025-05-14	SELL	-2,922	3.840	4.220	4.182	USD -12,220	12.39 Profit of 23,994 on sale
2025-04-30	SELL	-480	7.410	7.550	7.536	USD -3,617	13.05 Profit of 2,647 on sale
2025-04-28	SELL	-481	7.500	7.710	7.689	USD -3,698	13.17 Profit of 2,634 on sale
2025-04-25	SELL	-480	7.420	7.430	7.429	USD -3,566	13.22 Profit of 2,782 on sale
2025-04-11	SELL	-2,928	8.000	8.050	8.045	USD -23,556	13.72 Profit of 16,612 on sale
2025-04-08	SELL	-1,452	7.730	8.490	8.414	USD -12,217	13.91 Profit of 7,986 on sale
2025-04-07	BUY	8,009	8.070	8.630	8.574	USD 68,669	13.98
2025-03-31	SELL	-898	8.870	9.020	9.005	USD -8,086	14.24 Profit of 4,703 on sale
2025-03-21	SELL	-892	10.010	10.300	10.271	USD -9,162	14.62 Profit of 3,875 on sale
2025-03-12	SELL	-454	10.410	11.440	11.337	USD -5,147	15.08 Profit of 1,701 on sale
2025-02-28	SELL	-452	10.730	11.220	11.171	USD -5,049	15.71 Profit of 2,052 on sale
2025-02-25	BUY	450	11.740	12.280	12.226	USD 5,502	15.93
2025-02-20	SELL	-450	14.980	15.190	15.169	USD -6,826	16.02 Profit of 382 on sale
2025-02-19	BUY	900	14.900	15.470	15.413	USD 13,872	16.04
2025-02-18	BUY	450	14.570	14.900	14.867	USD 6,690	16.07
2024-12-30	SELL	-866	13.630	13.830	13.810	USD -11,959	17.88 Profit of 3,527 on sale
2024-12-06	SELL	-441	15.130	16.630	16.480	USD -7,268	18.16 Profit of 741 on sale
2024-12-04	SELL	-441	16.600	16.830	16.807	USD -7,412	18.28 Profit of 649 on sale
2024-12-03	SELL	-884	16.230	16.710	16.662	USD -14,729	18.36 Profit of 1,497 on sale
2024-11-21	SELL	-448	15.120	15.610	15.561	USD -6,971	19.35 Profit of 1,696 on sale
2024-11-20	SELL	-459	15.300	15.330	15.327	USD -7,035	19.57 Profit of 1,948 on sale
2024-11-19	SELL	-459	15.000	15.680	15.612	USD -7,166	19.84 Profit of 1,941 on sale
2024-11-18	SELL	-1,776	15.220	15.510	15.481	USD -27,494	20.13 Profit of 8,254 on sale
2024-11-12	SELL	-444	16.170	17.450	17.322	USD -7,691	20.39 Profit of 1,363 on sale
2024-11-07	SELL	-443	17.670	18.420	18.345	USD -8,127	20.83 Profit of 1,102 on sale
2024-11-05	SELL	-886	17.610	17.960	17.925	USD -15,882	21.42 Profit of 3,097 on sale
2024-10-28	SELL	-443	21.960	22.120	22.104	USD -9,792	22.17 Profit of 29 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MYGN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	98,797	0	263,141	37.5%
2025-09-18	87,796	0	406,688	21.6%
2025-09-17	144,056	0	336,241	42.8%
2025-09-16	159,582	0	394,910	40.4%
2025-09-15	173,531	0	356,200	48.7%
2025-09-12	273,006	0	766,551	35.6%
2025-09-11	264,844	3	855,095	31.0%
2025-09-10	115,504	0	320,173	36.1%
2025-09-09	117,829	0	834,127	14.1%
2025-09-08	293,509	0	568,194	51.7%
2025-09-05	142,110	0	429,582	33.1%
2025-09-04	90,037	0	255,788	35.2%
2025-09-03	187,849	0	373,122	50.3%
2025-09-02	417,098	140	736,942	56.6%
2025-08-29	210,744	0	471,701	44.7%
2025-08-28	218,735	0	367,389	59.5%
2025-08-27	141,025	0	200,611	70.3%
2025-08-26	124,117	0	205,575	60.4%
2025-08-25	130,424	23	225,719	57.8%
2025-08-22	167,087	0	332,617	50.2%
2025-08-21	227,679	0	355,895	64.0%
2025-08-20	274,774	10	542,346	50.7%
2025-08-19	182,975	14	441,628	41.4%
2025-08-18	197,831	0	527,427	37.5%
2025-08-15	209,896	0	350,467	59.9%
2025-08-14	326,239	0	825,822	39.5%
2025-08-13	283,844	0	647,800	43.8%
2025-08-12	241,652	0	445,084	54.3%
2025-08-11	333,298	0	591,643	56.3%
2025-08-08	353,287	0	848,909	41.6%
2025-08-07	1,045,983	2,164	2,050,524	51.0%
2025-08-06	3,016,810	8,355	7,314,581	41.2%
2025-08-05	346,937	248	635,531	54.6%
2025-08-04	156,295	0	344,862	45.3%
2025-08-01	183,779	0	522,493	35.2%
2025-07-31	353,605	0	1,022,681	34.6%
2025-07-30	197,169	0	561,414	35.1%
2025-07-29	246,810	1	630,254	39.2%
2025-07-28	143,502	0	424,457	33.8%
2025-07-25	192,399	207	475,911	40.4%
2025-07-24	147,034	100	277,917	52.9%
2025-07-23	119,803	0	313,290	38.2%
2025-07-22	160,482	2,781	420,473	38.2%
2025-07-21	117,593	0	293,239	40.1%
2025-07-18	173,798	0	453,121	38.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE